Changes in Nephritogenic Serum Galactose-deficient IgA1 in IgA Nephropathy Following Tonsillectomy and Steroid Therapy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Mar 4

PMID 24586974

Citations 47

Authors

Junichiro Nakata

Yusuke Suzuki

Hitoshi Suzuki

Daisuke Sato

Tatsuya Kano

Hiroyuki Yanagawa

Keiichi Matsuzaki

Satoshi Horikoshi

Jan Novak

Yasuhiko Tomino

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have shown that galactose-deficient IgA1 (GdIgA1) has an important role in the pathogenesis of IgA nephropathy (IgAN). Although emerging data suggest that serum GdIgA1 can be a useful non-invasive IgAN biomarker, the localization of nephritogenic GdIgA1-producing B cells remains unclear. Recent clinical and experimental studies indicate that immune activation tonsillar toll-like receptor (TLR) 9 may be involved in the pathogenesis of IgAN. Here we assessed the possibility of GdIgA1 production in the palatine tonsils in IgAN patients.

Methods: We assessed changes in serum GdIgA1 levels in IgAN patients with clinical remission of hematuria and proteinuria following combined tonsillectomy and steroid pulse therapy. Further, the association between clinical outcome and tonsillar TLR9 expression was evaluated.

Results: Patients (n = 37) were divided into two groups according to therapy response. In one group, serum GdIgA1 levels decreased after tonsillectomy (59%) alone, whereas in the other group most levels only decreased after the addition of steroid pulse therapy to tonsillectomy (41%). The former group showed significantly higher tonsillar TLR9 expression and better improvement in hematuria immediately after tonsillectomy than the latter group.

Conclusions: The present study indicates that the palatine tonsils are probably a major sites of GdIgA1-producing cells. However, in some patients these cells may propagate to other lymphoid organs, which may partially explain the different responses observed to tonsillectomy alone. These findings help to clarify some of the clinical observations in the management of IgAN, and may highlight future directions for research.

Citing Articles

Patients With Immunoglobulin A Nephropathy Show Abnormal Frequencies of B Cell Subsets, Unconventional T Cells, and High Levels of Galactose-Deficient IgA1-Coated Gut Bacteria.

Gentile M, Goerlich N, Lo I, Olson N, McConnell M, Pospiech J Kidney Int Rep. 2025; 10(2):475-488.

PMID: 39990906 PMC: 11843297. DOI: 10.1016/j.ekir.2024.11.007.

Tonsillectomy in Immunoglobulin A vasculitis with nephritis: case series.

Kubo E, Haruhara K, Marumoto H, Sasaki T, Okabe M, Yokote S CEN Case Rep. 2025; .

PMID: 39961993 DOI: 10.1007/s13730-025-00975-6.

Lessons from IgA Nephropathy Models.

Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M Int J Mol Sci. 2024; 25(21).

PMID: 39519036 PMC: 11546737. DOI: 10.3390/ijms252111484.

Effect of tonsillectomy combined with steroid pulse therapy upon IgA nephropathy depending on proteinuria status at diagnosis: a nationwide multicenter cohort study in Japan.

Komatsu H, Fujimoto S, Sato Y, Yasuda T, Yasuda Y, Matsuzaki K Clin Exp Nephrol. 2024; 28(12):1272-1281.

PMID: 38954311 PMC: 11621197. DOI: 10.1007/s10157-024-02530-6.

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy.

Yamada K, Huang Z, Reily C, Green T, Suzuki H, Novak J Kidney Int Rep. 2024; 9(2):423-435.

PMID: 38344714 PMC: 10851019. DOI: 10.1016/j.ekir.2023.11.003.

References

Floege J . Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004; 24(3):287-91. DOI: 10.1016/j.semnephrol.2004.01.008. View

Glassock R . IgA nephropathy: challenges and opportunities. Cleve Clin J Med. 2008; 75(8):569-76. DOI: 10.3949/ccjm.75.8.569. View

Berger J, HINGLAIS N . [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris). 1968; 74(9):694-5. View

Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T . Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008; 19(12):2384-95. PMC: 2588104. DOI: 10.1681/ASN.2007121311. View

Moldoveanu Z, Wyatt R, Lee J, Tomana M, Julian B, Mestecky J . Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007; 71(11):1148-54. DOI: 10.1038/sj.ki.5002185. View

Allen A, Bailey E, Brenchley P, Buck K, Barratt J, Feehally J . Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001; 60(3):969-73. DOI: 10.1046/j.1523-1755.2001.060003969.x. View

Sanfilippo F, Croker B, Bollinger R . Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation. 1982; 33(4):370-6. DOI: 10.1097/00007890-198204000-00006. View

van den Wall Bake A, Daha M, van Es L . Immunopathogenetic aspects of IgA nephropathy. Nephrologie. 1989; 10(3):141-5. View

van den Wall Bake A, Beyer W, Hermans J, Daha M, Masurel N, van Es L . Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. J Clin Invest. 1989; 84(4):1070-5. PMC: 329762. DOI: 10.1172/JCI114269. View

10.

Nishie T, Miyaishi O, Azuma H, Kameyama A, Naruse C, Hashimoto N . Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice. Am J Pathol. 2007; 170(2):447-56. PMC: 1851871. DOI: 10.2353/ajpath.2007.060559. View

11.

Emancipator S . Immunoregulatory factors in the pathogenesis of IgA nephropathy. Kidney Int. 1990; 38(6):1216-29. DOI: 10.1038/ki.1990.337. View

12.

Kunkel E, Butcher E . Plasma-cell homing. Nat Rev Immunol. 2003; 3(10):822-9. DOI: 10.1038/nri1203. View

13.

Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K . Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008; 3(5):1301-7. PMC: 2518790. DOI: 10.2215/CJN.00310108. View

14.

Kobayashi I, Nogaki F, Kusano H, Ono T, Miyawaki S, Yoshida H . Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels. Nephrol Dial Transplant. 2002; 17(12):2108-16. DOI: 10.1093/ndt/17.12.2108. View

15.

Feehally J . Immune mechanisms in glomerular IgA deposition. Nephrol Dial Transplant. 1988; 3(4):361-78. DOI: 10.1093/oxfordjournals.ndt.a091683. View

16.

Itoh A, Iwase H, Takatani T, Nakamura I, Hayashi M, Oba K . Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant. 2003; 18(6):1108-14. DOI: 10.1093/ndt/gfg108. View

17.

Iwanami N, Iwase H, Takahashi N, Kato K, Itoh A, Takatani T . Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum. J Nephrol. 2008; 21(1):118-26. View

18.

Tomana M, Novak J, Julian B, Matousovic K, Konecny K, Mestecky J . Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999; 104(1):73-81. PMC: 408399. DOI: 10.1172/JCI5535. View

19.

Roodnat J, de Fijter J, van Kooten C, Daha M, van Es L . Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant. 1999; 14(2):353-9. DOI: 10.1093/ndt/14.2.353. View

20.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian B . Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009; 119(6):1668-77. PMC: 2689118. DOI: 10.1172/JCI38468. View